Press Releases

Date Title and Summary Additional Formats
Toggle Summary Xencor and Astellas Enter Collaboration for Novel Bispecific Antibody Program
-- Partners to Generate Novel Bispecific Antibodies Directed Toward an Anti-tumor Target Identified by Astellas -- -- Astellas to Receive Exclusive Worldwide License to Potential Drug Candidates -- MONROVIA, Calif. --(BUSINESS WIRE)--Apr. 2, 2019-- Xencor, Inc.
View HTML
Toggle Summary Xencor to Participate in Upcoming Investor Conferences
MONROVIA, Calif. --(BUSINESS WIRE)--Apr. 1, 2019-- Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced that company management will
View HTML
Toggle Summary Xencor Announces Closing of Research Collaboration and License Agreement with Genentech
MONROVIA, Calif. --(BUSINESS WIRE)--Mar. 8, 2019-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today announced the closing of its research
View HTML
Toggle Summary Xencor Reports Fourth Quarter and Full Year 2018 Financial Results
- Initial Data from Phase 1 Study of XmAb®14045 Presented at ASH 2018; Multiple Complete Remissions Achieved in Advanced AML Patient Population; Study on Partial Clinical Hold Pending Resolution with FDA - - Research and License Agreement for XmAb®24306 and IL-15 Cytokines Provides $120 Million
View HTML
Toggle Summary Xencor Announces Partial Clinical Hold on Phase 1 Study of XmAb14045
MONROVIA, Calif. , Feb. 20, 2019 /PRNewswire/ --  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that the U.S.
View HTML
Toggle Summary Xencor to Host Fourth Quarter and Full Year 2018 Financial Results Webcast and Conference Call on February 25, 2019
MONROVIA, Calif. , Feb. 19, 2019 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that it will release fourth
View HTML
Toggle Summary Xencor to Present at Upcoming Investor Conferences
MONROVIA, Calif. , Feb. 7, 2019 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that company management will
View HTML
Toggle Summary Xencor to Develop and Commercialize Novel IL-15 Immune Activating Cytokines with Genentech
-- Xencor Receives $120 Million Upfront Payment, up to $180 Million in Development Milestones Per Program and Profit Share from Commercialized Medicines MONROVIA, Calif. , Feb. 5, 2019 /PRNewswire/ --  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered
View HTML
Toggle Summary Xencor Regains ex-U.S. Commercial Rights to XmAb®13676, CD20 x CD3 Bispecific Antibody
-- Initial data from the ongoing Phase 1 study in patients with B-cell malignancies expected in 2019 -- -- Xencor and Novartis to continue co-developing XmAb®14045, a CD123 x CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia -- MONROVIA, Calif. , Jan.
View HTML
Toggle Summary Xencor Presents Initial Data from Phase 1 Study of XmAb®14045 in Acute Myeloid Leukemia at the 2018 ASH Annual Meeting
MONROVIA, Calif. , Dec. 3, 2018 /PRNewswire/ --  Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today announced initial data from its ongoing Phase 1
View HTML
Xencor © Copyright 2019